HCW Biologics Inc.
HCWB- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001828673
In the last 90 days, HCW Biologics Inc. insiders filed 3 open-market purchases and 0 sales; 12 institutions reported holding it in 13F filings for Q2 2026, worth $515.7K in total; no superinvestor holds it.
13F holders, Q2 2026
Institutional positions in HCW Biologics Inc. as of Jun 30, 2026. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 12
- −3 vs. Q1 2026
- Shares held
- 103.5K
- +28.5K (+38.1%) vs. Q1 2026Converted for a 1-for-6 split
- Total value
- $515.7K
- +$354.8K (+220.6%) vs. Q1 2026
- New holders
- 3
- 4 more added
- Sold out
- 6
- 3 more reduced
Compare with Q1 2026: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting HCWB on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 12 | $515.7K |
| Q1 2026 | 15 | $160.8K |
| Q4 2025 | 14 | $424.1K |
| Q3 2025 | 10 | $456.9K |
| Q2 2025 | 8 | $85.5K |
| Q1 2025 | 15 | $326.0K |
| Q4 2024 | 18 | $1.40M |
| Q3 2024 | 16 | $625.6K |
| Q2 2024 | 19 | $784.3K |
| Q1 2024 | 20 | $1.90M |
| Q4 2023 | 19 | $1.30M |
| Q3 2023 | 14 | $1.93M |
| Q2 2023 | 13 | $2.17M |
| Q1 2023 | 13 | $1.22M |
| Q4 2022 | 14 | $1.50M |
| Q3 2022 | 13 | $1.50M |
| Q2 2022 | 13 | $1.25M |
| Q1 2022 | 13 | $1.48M |
| Q4 2021 | 13 | $855.0K |
| Q3 2021 | 9 | $512.0K |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q2 2026
Shares, value and share of portfolio for each institution holding HCW Biologics Inc.; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| UBS Group AG | 1 | $5 | 0.00% | −1,536−99.9% | ReducedConverted for a 1-for-6 split |
| Caitong International Asset Management Co., Ltd | 11 | $10 | 0.00% | +11 | New |
| Advisor Group Holdings, Inc. | 4 | $20 | 0.00% | −0−7.7% | ReducedConverted for a 1-for-6 split |
| Barclays PLC | 191 | $953 | 0.00% | +191 | New |
| Golden State Wealth Management, LLC | 1,667 | $8.32K | 0.00% | 00.0% | UnchangedConverted for a 1-for-6 split |
| Vanguard Capital Management LLC | 2,003 | $9.99K | 0.00% | 00.0% | UnchangedConverted for a 1-for-6 split |
| Connective Capital Management, LLC | 3,338 | $16.7K | 0.01% | +3,338 | New |
| Tower Research Capital LLC (TRC) | 4,117 | $20.5K | 0.00% | +1,644+66.5% | AddedConverted for a 1-for-6 split |
| Vanguard Fiduciary Trust Co | 6,510 | $32.5K | 0.00% | +6,193+1,952.5% | AddedConverted for a 1-for-6 split |
| HRT Financial LP | 13,583 | $67.0K | 0.00% | −30,816−69.4% | ReducedConverted for a 1-for-6 split |
| Citadel Advisors LLC | 19,942 | $99.5K | 0.00% | +15,595+358.7% | AddedConverted for a 1-for-6 split |
| Jane Street Group, LLC | 52,138 | $260.2K | 0.00% | +49,782+2,113.3% | AddedConverted for a 1-for-6 split |
| Virtu Financial LLC | 0 | $0 | 0.00% | −7,968−100.0% | Sold outConverted for a 1-for-6 split |
| Geode Capital Management, LLC | 0 | $0 | 0.00% | −5,981−100.0% | Sold outConverted for a 1-for-6 split |
| Citigroup Inc | 0 | $0 | 0.00% | −1,755−100.0% | Sold outConverted for a 1-for-6 split |
| Wells Fargo & Company | 0 | $0 | 0.00% | −167−100.0% | Sold outConverted for a 1-for-6 split |
| Northwestern Mutual Wealth Management Co | 0 | $0 | 0.00% | −0−100.0% | Sold outConverted for a 1-for-6 split |
| SBI Securities Co., Ltd. | 0 | $0 | 0.00% | −0−100.0% | Sold outConverted for a 1-for-6 split |